Omega-3 fatty acid supplementation on lipid profiles in dialysis patients: Meta-analysis

Archives of Medical Research

Volumn 45, Issue 6, 2014, Pages 469-477

  Chi, Honggang ^a   Lin, Xiaoru ^a   Huang, Haohai ^a   Zheng, Xuebao ^a   Li, Tao ^b   Zou, Ying ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Dialysis; Lipid; Meta analysis; Omega 3

Indexed keywords

ALBUMIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; HEMODIALYSIS PATIENT; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPLICATION; DIET SUPPLEMENTATION; DIET THERAPY; DYSLIPIDEMIAS; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; STATISTICAL MODEL; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CHOLESTEROL; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; FATTY ACIDS, OMEGA-3; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84908074761     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.06.008     Document Type: Article

References (41)

1. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(5 suppl 3):S112-S119.
2. Levin A., Foley R.N. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 2000, 36(6 suppl 3):S24-S30.
3. Wanner C., Zimmermann J., Quaschning T., et al. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int Suppl 1997, 62:S53-S55.
4. Cheung A.K. Is lipid control necessary in hemodialysis patients?. Clin J Am Soc Nephrol 2009, 4(suppl 1):S95-S101.
5. Fernandez-Reyes M.J., Alvarez-Ude F., Sanchez R., et al. Inflammation and malnutrition as predictors of mortality in patients on hemodialysis. J Nephrol 2002, 15:136-143.
6. Herselman M., Esau N., Kruger J.M., et al. Relationship between serum protein and mortality in adults on long-term hemodialysis: exhaustive review and meta-analysis. Nutrition 2010, 26:10-32.
7. Upadhyay A., Earley A., Lamont J.L., et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Int Med 2012, 157:251-262.
8. Rysz J., Aronow W.S., Stolarek R.S., et al. Nephroprotective and clinical potential of statins in dialyzed patients. Exp Opin Therap Targets 2009, 13:541-550.
9. Barylski M., Nikfar S., Mikhailidis D.P., et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013, 72:35-44.
10. Nikolic D., Banach M., Nikfar S., et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. Int J Cardiol 2013, 168:5437-5447.
11. Nikolic D., Nikfar S., Salari P., et al. Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opinion 2013, 29:435-451.
12. Banach M. Statins in patients with chronic kidney disease - an attempt at recommendations. Curr Med Res Opinion 2013, 29:1419-1422.
13. Cicero A.F., Reggi A., Parini A., et al. Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects. Arch Med Sci 2012, 8:784-793.
14. Dessi M., Noce A., Bertucci P., et al. Atherosclerosis, dyslipidemia, and inflammation: the significant role of polyunsaturated fatty acids. ISRN Inflamm 2013, 2013:191823.
15. Leaf A., Kang J.X., Xiao Y.F., et al. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003, 107:2646-2652.
16. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6:e1000100.
17. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Contr Clin Trials 1996, 17:1-12.
18. Kjaergard L.L., Villumsen J., Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001, 135:982-989.
19. Higgins J.P., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) 2011, The Cochrane Collaboration, http://www.cochrane.org/handbook.
20. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
21. Kooshki A., Taleban F.A., Tabibi H., et al. Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients. Ann Nutr Metab 2011, 58:197-202.
22. Kooshki A., Taleban F.A., Tabibi H., et al. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. Renal Failure 2011, 33:892-898.
23. Diskin C.J., Thomas C.E., Zellner C.P., et al. Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron 1990, 55:445-447.
24. Ando M., Sanaka T., Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents invivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999, 10:2177-2184.
25. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J Renal Nutr 2000, 10:191-195.
26. Schmitz P.G., McCloud L.K., Reikes S.T., et al. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol 2002, 13:184-190.
27. Saifullah A., Watkins B.A., Saha C., et al. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients-a pilot study. Nephrol Dial Transplant 2007, 22:3561-3567.
28. Taziki O., Lessan-Pezeshki M., Akha O., et al. The effect of low dose omega-3 on plasma lipids in hemodialysis patients. Saudi J Kidney Dis Transplant 2007, 18:571-576.
29. Svensson M., Schmidt E.B., Jorgensen K.A., et al. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrol Dial Transplant 2008, 23:2918-2924.
30. Bowden R.G., Jitomir J., Wilson R.L., et al. Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients. J Renal Nutr 2009, 19:259-266.
31. Bowden R.G., Wilson R.L., Deike E., et al. Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutr Clin Pract 2009, 24:508-512.
32. An W.S., Lee S.M., Son Y.K., et al. Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostagl Leukotr Essent Fatty Acids 2012, 86:29-34.
33. An W.S., Lee S.M., Son Y.K., et al. Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients. Nutr Res 2012, 32:495-502.
34. Lemos J.R., Alencastro M.G., Konrath A.V., et al. Flaxseed oil supplementation decreases C-reactive protein levels in chronic hemodialysis patients. Nutr Res 2012, 32:921-927.
35. Tayebi-Khosroshahi H., Dehgan R., Habibi Asl B., et al. Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients. Iranian J Kidney Dis 2013, 7:479-484.
36. Friedman A., Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol 2006, 1:182-192.
37. Lapillonne A., Clarke S.D., Heird W.C. Polyunsaturated fatty acids and gene expression. Curr Opin Clin Nutr Metabol Care 2004, 7:151-156.
38. Kliewer S.A., Sundseth S.S., Jones S.A., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sc USA 1997, 94:4318-4323.
39. Xu J., Nakamura M.T., Cho H.P., et al. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J Biol Chem 1999, 274:23577-23583.
40. Owen W.F., Lew N.L., Liu Y., et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993, 329:1001-1006.
41. Ikizler T.A., Morrow J.D., Roberts L.J., et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 2002, 58:190-197.